American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III: Low-dose-rate and pulsed-dose-rate brachytherapy

Larissa J. Lee, Indra J. Das, Susan A. Higgins, Anuja Jhingran, William Small, Bruce Thomadsen, Akila N. Viswanathan, Aaron Wolfson, Patricia Eifel

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Purpose: To develop a guideline for quality practice of low-dose-rate (LDR) and pulsed-dose-rate (PDR) brachytherapy for locally advanced cervical cancer. Methods: Members of the American Brachytherapy Society (ABS) with expertise in cervical cancer brachytherapy formulated updated guidelines for LDR and PDR brachytherapy for locally advanced (International Federation of Gynecology and Obstetrics [FIGO] Stages IB2-IVA) cervical cancer based on literature review and clinical experience. Results: The ABS strongly recommends the use of brachytherapy as a component of the definitive treatment of locally advanced cervical carcinoma. Precise applicator placement is necessary to maximize the probability of achieving local control without major side effects. The ABS recommends a cumulative delivered dose of approximately 80-90. Gy for definitive treatment. Dosimetry must be performed after each insertion before treatment delivery. The dose delivered to point A should be reported for all intracavitary brachytherapy applications regardless of treatment planning technique. The ABS also recommends adoption of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology guidelines for contouring, image-based treatment planning and dose reporting. Interstitial brachytherapy may be considered for a small proportion of patients whose disease cannot be adequately encompassed by intracavitary application and should be performed by practitioners with special expertise in these procedures. Quality management measures must be performed, and follow-up information should also be obtained. Conclusions: Updated ABS guidelines are provided for LDR and PDR brachytherapy for locally advanced cervical cancer. Practitioners and cooperative groups are encouraged to use these guidelines to formulate their clinical practices and to adopt dose-reporting policies that are critical for outcome analysis.

Original languageEnglish
Pages (from-to)53-57
Number of pages5
JournalBrachytherapy
Volume11
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Brachytherapy
Cervix Uteri
Guidelines
Carcinoma
Uterine Cervical Neoplasms
Planning Techniques
Therapeutics
Radiation Oncology
Gynecology
Practice Guidelines
Obstetrics

Keywords

  • Brachytherapy
  • Cervical cancer
  • Guidelines
  • Low-dose-rate
  • Pulsed-dose-rate

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III : Low-dose-rate and pulsed-dose-rate brachytherapy. / Lee, Larissa J.; Das, Indra J.; Higgins, Susan A.; Jhingran, Anuja; Small, William; Thomadsen, Bruce; Viswanathan, Akila N.; Wolfson, Aaron; Eifel, Patricia.

In: Brachytherapy, Vol. 11, No. 1, 01.01.2012, p. 53-57.

Research output: Contribution to journalArticle

Lee, Larissa J. ; Das, Indra J. ; Higgins, Susan A. ; Jhingran, Anuja ; Small, William ; Thomadsen, Bruce ; Viswanathan, Akila N. ; Wolfson, Aaron ; Eifel, Patricia. / American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III : Low-dose-rate and pulsed-dose-rate brachytherapy. In: Brachytherapy. 2012 ; Vol. 11, No. 1. pp. 53-57.
@article{bac0dbb413de417e9a23ecbc343e5ba1,
title = "American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III: Low-dose-rate and pulsed-dose-rate brachytherapy",
abstract = "Purpose: To develop a guideline for quality practice of low-dose-rate (LDR) and pulsed-dose-rate (PDR) brachytherapy for locally advanced cervical cancer. Methods: Members of the American Brachytherapy Society (ABS) with expertise in cervical cancer brachytherapy formulated updated guidelines for LDR and PDR brachytherapy for locally advanced (International Federation of Gynecology and Obstetrics [FIGO] Stages IB2-IVA) cervical cancer based on literature review and clinical experience. Results: The ABS strongly recommends the use of brachytherapy as a component of the definitive treatment of locally advanced cervical carcinoma. Precise applicator placement is necessary to maximize the probability of achieving local control without major side effects. The ABS recommends a cumulative delivered dose of approximately 80-90. Gy for definitive treatment. Dosimetry must be performed after each insertion before treatment delivery. The dose delivered to point A should be reported for all intracavitary brachytherapy applications regardless of treatment planning technique. The ABS also recommends adoption of the Groupe Europ{\'e}en de Curieth{\'e}rapie-European Society for Therapeutic Radiology and Oncology guidelines for contouring, image-based treatment planning and dose reporting. Interstitial brachytherapy may be considered for a small proportion of patients whose disease cannot be adequately encompassed by intracavitary application and should be performed by practitioners with special expertise in these procedures. Quality management measures must be performed, and follow-up information should also be obtained. Conclusions: Updated ABS guidelines are provided for LDR and PDR brachytherapy for locally advanced cervical cancer. Practitioners and cooperative groups are encouraged to use these guidelines to formulate their clinical practices and to adopt dose-reporting policies that are critical for outcome analysis.",
keywords = "Brachytherapy, Cervical cancer, Guidelines, Low-dose-rate, Pulsed-dose-rate",
author = "Lee, {Larissa J.} and Das, {Indra J.} and Higgins, {Susan A.} and Anuja Jhingran and William Small and Bruce Thomadsen and Viswanathan, {Akila N.} and Aaron Wolfson and Patricia Eifel",
year = "2012",
month = "1",
day = "1",
doi = "10.1016/j.brachy.2011.07.001",
language = "English",
volume = "11",
pages = "53--57",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - American Brachytherapy Society consensus guidelines for locally advanced carcinoma of the cervix. Part III

T2 - Low-dose-rate and pulsed-dose-rate brachytherapy

AU - Lee, Larissa J.

AU - Das, Indra J.

AU - Higgins, Susan A.

AU - Jhingran, Anuja

AU - Small, William

AU - Thomadsen, Bruce

AU - Viswanathan, Akila N.

AU - Wolfson, Aaron

AU - Eifel, Patricia

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Purpose: To develop a guideline for quality practice of low-dose-rate (LDR) and pulsed-dose-rate (PDR) brachytherapy for locally advanced cervical cancer. Methods: Members of the American Brachytherapy Society (ABS) with expertise in cervical cancer brachytherapy formulated updated guidelines for LDR and PDR brachytherapy for locally advanced (International Federation of Gynecology and Obstetrics [FIGO] Stages IB2-IVA) cervical cancer based on literature review and clinical experience. Results: The ABS strongly recommends the use of brachytherapy as a component of the definitive treatment of locally advanced cervical carcinoma. Precise applicator placement is necessary to maximize the probability of achieving local control without major side effects. The ABS recommends a cumulative delivered dose of approximately 80-90. Gy for definitive treatment. Dosimetry must be performed after each insertion before treatment delivery. The dose delivered to point A should be reported for all intracavitary brachytherapy applications regardless of treatment planning technique. The ABS also recommends adoption of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology guidelines for contouring, image-based treatment planning and dose reporting. Interstitial brachytherapy may be considered for a small proportion of patients whose disease cannot be adequately encompassed by intracavitary application and should be performed by practitioners with special expertise in these procedures. Quality management measures must be performed, and follow-up information should also be obtained. Conclusions: Updated ABS guidelines are provided for LDR and PDR brachytherapy for locally advanced cervical cancer. Practitioners and cooperative groups are encouraged to use these guidelines to formulate their clinical practices and to adopt dose-reporting policies that are critical for outcome analysis.

AB - Purpose: To develop a guideline for quality practice of low-dose-rate (LDR) and pulsed-dose-rate (PDR) brachytherapy for locally advanced cervical cancer. Methods: Members of the American Brachytherapy Society (ABS) with expertise in cervical cancer brachytherapy formulated updated guidelines for LDR and PDR brachytherapy for locally advanced (International Federation of Gynecology and Obstetrics [FIGO] Stages IB2-IVA) cervical cancer based on literature review and clinical experience. Results: The ABS strongly recommends the use of brachytherapy as a component of the definitive treatment of locally advanced cervical carcinoma. Precise applicator placement is necessary to maximize the probability of achieving local control without major side effects. The ABS recommends a cumulative delivered dose of approximately 80-90. Gy for definitive treatment. Dosimetry must be performed after each insertion before treatment delivery. The dose delivered to point A should be reported for all intracavitary brachytherapy applications regardless of treatment planning technique. The ABS also recommends adoption of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology guidelines for contouring, image-based treatment planning and dose reporting. Interstitial brachytherapy may be considered for a small proportion of patients whose disease cannot be adequately encompassed by intracavitary application and should be performed by practitioners with special expertise in these procedures. Quality management measures must be performed, and follow-up information should also be obtained. Conclusions: Updated ABS guidelines are provided for LDR and PDR brachytherapy for locally advanced cervical cancer. Practitioners and cooperative groups are encouraged to use these guidelines to formulate their clinical practices and to adopt dose-reporting policies that are critical for outcome analysis.

KW - Brachytherapy

KW - Cervical cancer

KW - Guidelines

KW - Low-dose-rate

KW - Pulsed-dose-rate

UR - http://www.scopus.com/inward/record.url?scp=84856007390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856007390&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2011.07.001

DO - 10.1016/j.brachy.2011.07.001

M3 - Article

C2 - 22265438

AN - SCOPUS:84856007390

VL - 11

SP - 53

EP - 57

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

IS - 1

ER -